Key Points
- CFO Mark Ragosa sold 12,000 KNSA shares on Jan. 8 at an average price of $41.89 for $502,680, leaving him with 19,086 shares — a 38.6% reduction in his ownership.
- The Jan. 8 sale continues a string of large insider dispositions (Dec. 8: 42,841 shares for $1.78M; Nov. 12: 19,900 shares for $814,706), indicating substantial ongoing insider selling.
- Kiniksa (KNSA) opened at $42.67 (near its 52‑week high of $44.42), has a market cap of about $3.23B, and carries a consensus analyst rating of Moderate Buy with a $52 target.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 12,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $41.89, for a total value of $502,680.00. Following the completion of the transaction, the chief financial officer directly owned 19,086 shares of the company's stock, valued at $799,512.54. This trade represents a 38.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Mark Ragosa also recently made the following trade(s):
- On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.49, for a total value of $1,777,473.09.
- On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $40.94, for a total value of $814,706.00.
- On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total transaction of $4,100.00.
Kiniksa Pharmaceuticals International Stock Up 2.3%
Shares of KNSA opened at $42.67 on Friday. The firm has a 50-day moving average price of $41.26 and a 200 day moving average price of $36.31. The firm has a market capitalization of $3.23 billion, a PE ratio of 94.82 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $44.42.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts' consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm's quarterly revenue was up 61.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.18) earnings per share. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after buying an additional 532 shares during the period. Mariner LLC increased its position in shares of Kiniksa Pharmaceuticals International by 5.8% in the third quarter. Mariner LLC now owns 13,253 shares of the company's stock worth $515,000 after acquiring an additional 732 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company's stock valued at $701,000 after acquiring an additional 771 shares during the period. USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $32,000. Finally, Nordea Investment Management AB boosted its stake in Kiniksa Pharmaceuticals International by 0.7% in the 3rd quarter. Nordea Investment Management AB now owns 131,074 shares of the company's stock worth $5,016,000 after purchasing an additional 914 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently issued reports on KNSA. TD Cowen started coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a "buy" rating and a $60.00 price target on the stock. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Wednesday, October 29th. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Finally, Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of "Moderate Buy" and a consensus target price of $52.00.
View Our Latest Stock Analysis on KNSA
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
